Maynard Um
-
-
-
-
-
-
-
Citius Oncology signs distribution deal with McKesson for LYMPHIR launch
-
-
-
-
-
-
-
Citius Oncology (CTOR) stock soars on distribution deal
-
-
-
-
-
-
-
Citius Pharmaceuticals (CTXR) and Citius Oncology (CTOR) Highlight LYMPHIR Commercial Launch Planned for H1 of 2025
-
-
-
-
-
-
-
Citius Pharmaceuticals (CTXR) Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
-
-
-
-
-
-
-
Citius Pharmaceuticals (CTXR) Details Near-Term Milestones for Late-Stage Candidates
405,028 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

